Is AMRX Stock Undervalued? Sales Multiple, Target, and Upside
Amneal Pharmaceuticals, or AMRX as it’s known on the ticker, has spent the last year building serious momentum. By balancing broad-based growth across its generics division with a specialty pharma push and government-focused distribution, the company has managed to post higher revenues and improved earnings. Honestly, the 2025 results were a masterclass in mix improvement and disciplined cost management, particularly regarding interest expenses. But the market isn’t looking at 2025 anymore. Attention has shifted sharply to 2026, which is shaping up to be a classic transition year for the firm. With Rytary facing generic erosion, the company is betting heavily on its ability to execute across a complex, high-margin portfolio.
At first glance, the valuation story for AMRX is a bit of a head-scratcher.
Even after a massive 83.4% run over the last twelve months, AMRX stock still trades at a discount compared to its peers. We are looking at a sales multiple of about 1.39x trailing 12-month sales per share. Compare that to the broader Zacks Medical sector, which sits closer to 2.5x, or the S&P 500 at 5.72x, and you start to see why analysts are split. While the current multiple is technically above the company’s own five-year median of 0.41x, it remains compressed against market benchmarks. It seems the market is playing a game of “wait and see,” balancing the company’s undeniable fundamental improvements against the lingering, stubborn uncertainty surrounding pricing pressures in the U.S. generics market.
Management has laid out a clear road map for 2026, targeting revenues between $3.05 billion and $3.1 billion. They are projecting adjusted earnings per share in the $0.93 to $1.03 range. To hit these numbers, the company needs a flawless execution strategy. Growth in the Affordable Medicines segment is expected to hover around 7% to 8%, but the Specialty side is projected to remain flat as new product growth tries to offset the decline of older assets. Maintaining gross margin discipline while navigating the regulatory minefield of biosimilars and complex injectables is the ultimate test. It’s a demanding path, but the company’s recent efforts to refinance debt and extend maturities to 2032 suggest they have the financial runway to handle the noise.
Cash flow remains the quiet hero of the narrative. With operating cash flow sitting at approximately $340 million for 2025, Amneal is finally making meaningful progress on the balance sheet. They’ve successfully chipped away at net leverage, bringing it down to 3.5x from the 3.9x seen at the end of 2024. This deleveraging effort is vital; it provides a necessary cushion against the volatility that inevitably accompanies drug launches and patent cliffs. By securing lower financing costs, the firm has essentially bought itself more time to pivot toward its newer, higher-margin growth drivers, like the partnership tied to GLP-1 related metabolic therapies.
Looking at the bull case, the argument rests on pure, unadulterated diversification. Amneal isn’t betting the farm on a single product. With a portfolio that spans roughly 300 different medicines, they are well-positioned to weather the cyclical storms of the pharma industry. However, the bear case is just as loud. Pricing pressure from pharmacy chains is a structural reality that could keep the AMRX valuation suppressed even if volume growth remains steady. As US News Hub Misryoum analysts note, the $14.00 price target, based on a 1.5x sales multiple, hinges entirely on the company’s ability to prove that its growth algorithm is durable enough to survive the coming year’s transition.